Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders

[Image: see text] Activated coagulation factor XI (FXIa) is a highly attractive antithrombotic target as it contributes to the development and progression of thrombosis but is thought to play only a minor role in hemostasis so that its inhibition may allow for decoupling of antithrombotic efficacy a...

Descripción completa

Detalles Bibliográficos
Autores principales: Roehrig, Susanne, Ackerstaff, Jens, Jiménez Núñez, Eloísa, Teller, Henrik, Ellerbrock, Pascal, Meier, Katharina, Heitmeier, Stefan, Tersteegen, Adrian, Stampfuss, Jan, Lang, Dieter, Schlemmer, Karl-Heinz, Schaefer, Martina, Gericke, Kersten M., Kinzel, Tom, Meibom, Daniel, Schmidt, Martina, Gerdes, Christoph, Follmann, Markus, Hillisch, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510402/
https://www.ncbi.nlm.nih.gov/pubmed/37669040
http://dx.doi.org/10.1021/acs.jmedchem.3c00795

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10510402/
https://www.ncbi.nlm.nih.gov/pubmed/37669040
http://dx.doi.org/10.1021/acs.jmedchem.3c00795

Ejemplares similares